Introduction Psoriasis is a chronic inflammatory systemic disorder which is strongly associated with metabolic syndrome.Erythrodermic psoriasis(EP)is a severe type of psoriasis that causes severe physical and mental i...Introduction Psoriasis is a chronic inflammatory systemic disorder which is strongly associated with metabolic syndrome.Erythrodermic psoriasis(EP)is a severe type of psoriasis that causes severe physical and mental impairment.Evidence-based data on EP treatment are limited in recent years.Although conventional systemic treatments such as acitretin,cyclosporine,methotrexate and steroids show efficacy in patients with EP,these treatments have many limitations and intolerance[1].Improvement of this syndrome can seriously affect patients’quality of life(DLQI).Secukinumab is an interleukin-17A inhibitor human monoclonal antibody which has been approved for the treatment of moderate to severe plaque psoriasis[2].There has been no research on the use of secukinumab in EP patients with metabolic syndrome.We present two EP patients with metabolic syndrome who achieved and maintained successful treatment and remission for more than 52 weeks with secukinumab.展开更多
目的探讨窄谱中波紫外线(Narrow Band Ultraviolet B,NB-UVB)联合白细胞介素-17A(IL-17A)抑制剂Secukinumab治疗对寻常型银屑病患者细胞因子水平的影响。方法将118例寻常型银屑病患者按照随机数字表法分为对照组和观察组,对照组59例采取...目的探讨窄谱中波紫外线(Narrow Band Ultraviolet B,NB-UVB)联合白细胞介素-17A(IL-17A)抑制剂Secukinumab治疗对寻常型银屑病患者细胞因子水平的影响。方法将118例寻常型银屑病患者按照随机数字表法分为对照组和观察组,对照组59例采取NB-UVB治疗,观察组59例采取NB-UVB照射联合Secukinumab治疗,治疗周期均为8周,比较2组IL-1β、IL-17A、IL-22、辅助性T细胞22(Th22)、Th17水平,以银屑病的皮损严重程度和面积(PASI)评分评价2组临床疗效。结果观察组总有效率明显高于对照组(P<0.05)。治疗后,2组IL-1β、IL-17A、IL-22、Th22、Th17水平均较治疗前明显降低(P均<0.05),且观察组明显低于对照组(P均<0.05)。结论 NB-UVB照射联合Secukinumab治疗寻常型银屑病较单用NB-UVB照射具有更好的疗效,其作用机制可能是调节患者血清中IL-17A、IL-22水平,从而抑制Th22、Th17细胞介导的炎症反应。展开更多
Background:There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis.We conducted a real-life cohort study to investigate the efficacy and...Background:There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis.We conducted a real-life cohort study to investigate the efficacy and safety of secukinumab 150 and 300 mg in Chinese patients with moderate-to-severe plaque psoriasis.Methods:A total of 106 patients with moderate-to-severe plaque psoriasis were included in this study.Patients received either secukinumab 150 mg or secukinumab 300 mg according to patients’weights and severity of psoriasis.The treatment continued for at least 24 weeks.The efficacy was evaluated by improvement in the psoriasis area and severity index(PASI)scores.The safety was also analyzed.Results:Fifty-nine patients(55.7%)were treated with secukinumab 300 mg and 47 patients(44.3%)were treated with secukinumab 150 mg.After 12-week treatment,PASI75/90/100 responses were achieved in 100%,97.8%,and 95.7%of patients,respectively,in secukinumab 150 mg group,and the efficacy was maintained to week 24.In secukinumab 300 mg group,PASI75/90/100 responses were achieved in 93.2%,81.4%,and 76.3%of patients,respectively,at week 12.In this group,PASI75/90/100 responses reached 91.5%,86.4%,and 79.9%,respectively,at week 24.Biologic-experienced patients had lower responses than biologic-naïve patients.Secukinumab 150 and 300 mg were well tolerated.Five patients discontinued treatment due to poor response,adverse event,or economic reasons.Conclusions:This real-life study demonstrated that high PASI 90 and PASI 100 responses were achieved in Chinese psoriasis patients receiving secukinumab 150 or 300 mg.Biologic-naïve was associated with better clinical efficacy.展开更多
目的:观察司库奇尤单抗联合窄谱中波紫外线(UVB)照射治疗中重度斑块型银屑病疗效及对患者银屑病面积和严重程度指数(Psoriasis area and severity index,PASI)评分及血清免疫球蛋白、炎症因子的影响。方法:选取2021年1月-2023年7月笔者...目的:观察司库奇尤单抗联合窄谱中波紫外线(UVB)照射治疗中重度斑块型银屑病疗效及对患者银屑病面积和严重程度指数(Psoriasis area and severity index,PASI)评分及血清免疫球蛋白、炎症因子的影响。方法:选取2021年1月-2023年7月笔者医院皮肤科就诊的80例中重度斑块型银屑病患者,按随机数字表法分为观察组和对照组各40例。对照组予以窄谱UVB照射治疗,观察组予以司库奇尤单抗联合窄谱UVB照射治疗。两组患者均治疗观察12周,评价临床疗效、治疗前后PASI及皮肤病生活质量指数(Dermatology life quality index,DLQI)评分;检测患者血清免疫球蛋白(IgE、IgA、IgG)及白介素-17(IL-17)、白介素-23(IL-23)、肿瘤坏死因子-α(TNF-α)水平,记录不良反应情况。结果:治疗后,观察组总有效率95.00%,高于对照组的80.00%(P<0.05)。治疗后,两组患者PASI、DLQI评分均较治疗前下降,且观察组PASI、DLQI评分均较对照组低(P<0.05)。治疗后,两组患者血清IgE、IgA、IgG及IL-17、IL-23、TNF-α水平均较治疗前下降,且观察组血清IgE、IgA、IgG及IL-17、IL-23、TNF-α水平均较对照组低(P<0.05)。观察组不良反应总发生率15.00%,与对照组的7.50%比较差异无统计学意义(P>0.05)。结论:司库奇尤单抗联合窄谱UVB照射治疗中重度斑块型银屑病,相较单独窄谱UVB治疗效果更佳,有助于减轻症状、调节免疫功能、抑制炎症水平,对提高患者生活质量有积极意义,且未明显增加不良反应。展开更多
文摘Introduction Psoriasis is a chronic inflammatory systemic disorder which is strongly associated with metabolic syndrome.Erythrodermic psoriasis(EP)is a severe type of psoriasis that causes severe physical and mental impairment.Evidence-based data on EP treatment are limited in recent years.Although conventional systemic treatments such as acitretin,cyclosporine,methotrexate and steroids show efficacy in patients with EP,these treatments have many limitations and intolerance[1].Improvement of this syndrome can seriously affect patients’quality of life(DLQI).Secukinumab is an interleukin-17A inhibitor human monoclonal antibody which has been approved for the treatment of moderate to severe plaque psoriasis[2].There has been no research on the use of secukinumab in EP patients with metabolic syndrome.We present two EP patients with metabolic syndrome who achieved and maintained successful treatment and remission for more than 52 weeks with secukinumab.
文摘目的探讨窄谱中波紫外线(Narrow Band Ultraviolet B,NB-UVB)联合白细胞介素-17A(IL-17A)抑制剂Secukinumab治疗对寻常型银屑病患者细胞因子水平的影响。方法将118例寻常型银屑病患者按照随机数字表法分为对照组和观察组,对照组59例采取NB-UVB治疗,观察组59例采取NB-UVB照射联合Secukinumab治疗,治疗周期均为8周,比较2组IL-1β、IL-17A、IL-22、辅助性T细胞22(Th22)、Th17水平,以银屑病的皮损严重程度和面积(PASI)评分评价2组临床疗效。结果观察组总有效率明显高于对照组(P<0.05)。治疗后,2组IL-1β、IL-17A、IL-22、Th22、Th17水平均较治疗前明显降低(P均<0.05),且观察组明显低于对照组(P均<0.05)。结论 NB-UVB照射联合Secukinumab治疗寻常型银屑病较单用NB-UVB照射具有更好的疗效,其作用机制可能是调节患者血清中IL-17A、IL-22水平,从而抑制Th22、Th17细胞介导的炎症反应。
文摘Background:There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis.We conducted a real-life cohort study to investigate the efficacy and safety of secukinumab 150 and 300 mg in Chinese patients with moderate-to-severe plaque psoriasis.Methods:A total of 106 patients with moderate-to-severe plaque psoriasis were included in this study.Patients received either secukinumab 150 mg or secukinumab 300 mg according to patients’weights and severity of psoriasis.The treatment continued for at least 24 weeks.The efficacy was evaluated by improvement in the psoriasis area and severity index(PASI)scores.The safety was also analyzed.Results:Fifty-nine patients(55.7%)were treated with secukinumab 300 mg and 47 patients(44.3%)were treated with secukinumab 150 mg.After 12-week treatment,PASI75/90/100 responses were achieved in 100%,97.8%,and 95.7%of patients,respectively,in secukinumab 150 mg group,and the efficacy was maintained to week 24.In secukinumab 300 mg group,PASI75/90/100 responses were achieved in 93.2%,81.4%,and 76.3%of patients,respectively,at week 12.In this group,PASI75/90/100 responses reached 91.5%,86.4%,and 79.9%,respectively,at week 24.Biologic-experienced patients had lower responses than biologic-naïve patients.Secukinumab 150 and 300 mg were well tolerated.Five patients discontinued treatment due to poor response,adverse event,or economic reasons.Conclusions:This real-life study demonstrated that high PASI 90 and PASI 100 responses were achieved in Chinese psoriasis patients receiving secukinumab 150 or 300 mg.Biologic-naïve was associated with better clinical efficacy.
文摘目的:观察司库奇尤单抗联合窄谱中波紫外线(UVB)照射治疗中重度斑块型银屑病疗效及对患者银屑病面积和严重程度指数(Psoriasis area and severity index,PASI)评分及血清免疫球蛋白、炎症因子的影响。方法:选取2021年1月-2023年7月笔者医院皮肤科就诊的80例中重度斑块型银屑病患者,按随机数字表法分为观察组和对照组各40例。对照组予以窄谱UVB照射治疗,观察组予以司库奇尤单抗联合窄谱UVB照射治疗。两组患者均治疗观察12周,评价临床疗效、治疗前后PASI及皮肤病生活质量指数(Dermatology life quality index,DLQI)评分;检测患者血清免疫球蛋白(IgE、IgA、IgG)及白介素-17(IL-17)、白介素-23(IL-23)、肿瘤坏死因子-α(TNF-α)水平,记录不良反应情况。结果:治疗后,观察组总有效率95.00%,高于对照组的80.00%(P<0.05)。治疗后,两组患者PASI、DLQI评分均较治疗前下降,且观察组PASI、DLQI评分均较对照组低(P<0.05)。治疗后,两组患者血清IgE、IgA、IgG及IL-17、IL-23、TNF-α水平均较治疗前下降,且观察组血清IgE、IgA、IgG及IL-17、IL-23、TNF-α水平均较对照组低(P<0.05)。观察组不良反应总发生率15.00%,与对照组的7.50%比较差异无统计学意义(P>0.05)。结论:司库奇尤单抗联合窄谱UVB照射治疗中重度斑块型银屑病,相较单独窄谱UVB治疗效果更佳,有助于减轻症状、调节免疫功能、抑制炎症水平,对提高患者生活质量有积极意义,且未明显增加不良反应。
